MVC was granted National Innovation Award for the application of cell-based production technologies in mock-up vaccine manufacturing

The National Innovation Award, organized by the Institute for Biotechnology and Medicine Industry (IBMI), is an annual ceremony honoring important achievements and advance in the biomedical industry. This year, Medigen Vaccine Biologics Co. (MVC) received the National Innovation Award on Dec. 24th for the application of cell-based production technologies in mock-up vaccine manufacturing, recognized as an outstanding technology in the category of Industry Innovation.

Unlike traditional vaccine production method using specific-pathogen-free (SPF) embryonated eggs, cell-based production is more efficient in upscale production, quality control and provide more consistent supply. MVC is highly experienced in cell-based manufacturing platform and develops unique technologies to manufacture mock-up vaccines. In case of influenza outbreak, MVC can immediately initiate vaccine production once the virus strain is available and bring the product to the market through accelerated review pathway to timely prevent the spread of the epidemic.

MVC’s mock-up vaccine against H7N9 virus has successfully entered clinical trials. After completing pilot production next year, MVC will submit registration dossier to TFDA, aiming to obtain Taiwan’s first license in cell-based mock up vaccine.

[新聞1]基亞疫苗國家新創獎
MVC was granted 2015 National Innovation Award. MVC Chief Executive Dr. Chang received the award from Mr. Wang Jin-Pyng, founder of IBMI and President of Taiwan’s Legislative Yuan, in the award ceremony on December 24th.